Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,740 stopped studies mapped to Lymphoma and descendants · 89% state a reason
Over the 1,740 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00003605 | Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV… | Phase 2 | withdrawn | Aug 4, 2004 | Hoag Memorial Hospital Presbyterian | no patient accrual | Enrollment / accrual |
| NCT00003663 | Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent… | Phase 2 | withdrawn | Aug 4, 2004 | Hoag Memorial Hospital Presbyterian | no patient accrual | Enrollment / accrual |
| NCT00004039 | Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With… | Phase 2 | withdrawn | Aug 5, 2004 | Hoag Memorial Hospital Presbyterian | No patient accruals | Enrollment / accrual |
| NCT00954005 | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma(R-GO) | Phase 1 / Phase 2 | terminated | Aug 6, 2009 | German Low Grade Lymphoma Study Group | Predefined termination criterion of \> 10 patients without CR or PR was matched. | Other (stated, no rule matched) |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Mar 30, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00250718 | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | Phase 2 | terminated | Nov 8, 2005 | New Mexico Cancer Research Alliance | Low rate of accrual | Enrollment / accrual |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With… | Phase 1 | terminated | Jun 28, 2013 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous…(PXD101-CLN-6) | Phase 2 | terminated | Jan 11, 2006 | Valerio Therapeutics | Enrollment stopped prior to reaching expected number of patients, study had accumulated sufficient… | Enrollment / accrual |
| NCT01642563 | Italian Platelet Technology Assessment Study(IPTAS) | Phase 3 | terminated | Jul 17, 2012 | Centro Nazionale Sangue | Patient enrolment below planned schedule | Enrollment / accrual |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular… | Phase 2 | terminated | Aug 15, 2006 | National Cancer Institute (NCI) | Study terminated due to low accrual and the investigator left the NIH. | Investigator |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | terminated | Dec 22, 2011 | Duke University | Low accrual due to the approval of new drugs for use in Mantle cell lymphoma. | Enrollment / accrual |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed,… | Phase 2 | terminated | Feb 5, 2007 | Valerio Therapeutics | Terminated due to dose limiting toxicity | Safety / toxicity |
| NCT00358982 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | Phase 2 | terminated | Aug 1, 2006 | Mirati Therapeutics Inc. | not stated | Not stated |
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed… | Phase 2 | terminated | Oct 15, 2007 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With… | Phase 3 | terminated | Aug 29, 2007 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT01016795 | Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma(SCF980266) | Phase 2 | terminated | Nov 20, 2009 | Aalborg University Hospital | Study closed Nov 2000 by Amgen, who stopped drug delivery | Other (stated, no rule matched) |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01490047 | Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced… | Phase 1 | withdrawn | Dec 12, 2011 | Ludwig Institute for Cancer Research | not stated | Not stated |
| NCT00800150 | Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By… | Phase 1 | terminated | Dec 1, 2008 | City of Hope Medical Center | Protocol objective could not be met. A new study with amended eligibility criteria will be… | Other (stated, no rule matched) |
| NCT00952185 | Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant… | N/A | terminated | Aug 6, 2009 | City of Hope Medical Center | Very low enrollment and follow-up, cannot meet study objectives | Enrollment / accrual |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | withdrawn | May 1, 2013 | Stefan Schieke MD | not stated | Not stated |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | Phase 1 | terminated | May 3, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable. Study did not progress to Phase 2. | Other (stated, no rule matched) |
| NCT00500240 | Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute… | Phase 3 | terminated | Jul 12, 2007 | M.D. Anderson Cancer Center | Terminated early due to futility. | Efficacy / futility |
| NCT00770419 | Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers | — | withdrawn | Oct 10, 2008 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT02310997 | Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)(MAC UCBT) | Phase 2 | terminated | Dec 8, 2014 | University College, London | Trial closed early due to poor recruitment | Enrollment / accrual |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | Phase 1 / Phase 2 | terminated | Aug 11, 2005 | University of Michigan | Slow enrollment | Enrollment / accrual |
| NCT02150928 | An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze®… | Phase 2 | withdrawn | May 30, 2014 | Jazz Pharmaceuticals | not stated | Not stated |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00498667 | The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting… | — | withdrawn | Jul 10, 2007 | Rambam Health Care Campus | not stated | Not stated |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients… | Phase 2 | terminated | Nov 6, 2006 | Genzyme, a Sanofi Company | Enrollment terminated in 2005 to focus on Phase 3 study enrollment. | Enrollment / accrual |
| NCT00024115 | BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic… | Phase 1 | withdrawn | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple… | Phase 2 | withdrawn | Mar 10, 2014 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Sep 27, 2004 | GlaxoSmithKline | Acquired asset | Other (stated, no rule matched) |
| NCT00127101 | An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in… | Phase 1 | terminated | Aug 5, 2005 | Merck Sharp & Dohme LLC | The study was stopped due to low enrollment. | Enrollment / accrual |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab… | Phase 3 | withdrawn | Apr 27, 2006 | GlaxoSmithKline | This study has been cancelled prior to enrollment | Enrollment / accrual |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | Phase 2 | withdrawn | Jul 19, 2007 | Meir Medical Center | We found out that there is another study on the same issue | Other (stated, no rule matched) |
| NCT01050439 | Unrelated Donor Transplant for Malignant and Non-Malignant Disorders | Phase 2 | terminated | Jan 15, 2010 | Columbia University | PI left the institution | Investigator |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients… | Phase 4 | withdrawn | Oct 20, 2005 | Novartis | not stated | Not stated |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed… | Phase 2 | withdrawn | Jun 30, 2008 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | not stated | Not stated |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Feb 4, 2010 | University of Arkansas | Slow accrual; PI left primary institution | Investigator |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | Phase 2 | terminated | Sep 21, 2005 | International Extranodal Lymphoma Study Group (IELSG) | After IELSG25A study amendment, patients subject of the present study were eligible for inclusion… | Other (stated, no rule matched) |
| NCT01100658 | Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | N/A | terminated | Apr 9, 2010 | University of Minnesota | Due to slow accrual | Enrollment / accrual |
| NCT00077961 | Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular,… | Phase 1 / Phase 2 | terminated | Feb 18, 2004 | Genzyme, a Sanofi Company | not stated | Not stated |
| NCT00748631 | Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.(KYPHOK) | N/A | terminated | Sep 8, 2008 | Assistance Publique - Hôpitaux de Paris | the data collected are enough to obtain a qualitative analysis. | Other (stated, no rule matched) |
| NCT00068302 | Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or… | Phase 1 | terminated | Sep 11, 2003 | Children's Hospital of Philadelphia | Recruiting/enrolling participants halted prematurely but potentially will resume | Enrollment / accrual |
| NCT00185679 | Haploid Allogeneic Transplant Using the CliniMACS System | Phase 2 | terminated | Sep 16, 2005 | Ginna Laport | This study was superseded by the subsequent study IRB-15919 (NCT01050764) | Other (stated, no rule matched) |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 2 | terminated | Feb 2, 2015 | University of Colorado, Denver | Principle investigator left the institution | Investigator |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients… | Phase 1 / Phase 2 | terminated | Feb 2, 2015 | University of Colorado, Denver | Principle investigator left the institution | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Aug 20, 2015source: clinicaltrials